Pacira BioSciences, Inc. PCRX R2K
Company Overview
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Why Investors Should Care
Revenue has grown at a 27.4% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $726.41M (+3.6% YoY); net profit $7.03M.
- Trailing 12 Months Year-on-year growth — revenue +5.0%, earnings -30.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.4%, profit CAGR -45.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.44% |
| 1 Year: | 5.00% |
Compounded Profit Growth
| 5 Years: | -45.44% |
| 1 Year: | -30.00% |
Stock Price Performance
| 1 Year: | +8.67% |
| 6 Months: | +10.47% |
| 3 Months: | +6.65% |
| 1 Month: | +10.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.78 · Neutral
P/E of 194.85 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 194.8.
- Earnings shrank at -45.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PCRX Pacira BioSciences, Inc. R2K | 25.33 | 194.85 | $996.68M | 0.00% | 1.68% | 0.71% | 27.44% | -45.44% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 68.42M | 70.14M | 66.95M | - | 74.29M | 80.72M | 82.71M | - | 90.91M | 101.82M | 104.35M | - | 105.68M | 75.50M | 117.48M | - | 119.03M | 135.59M | 127.72M | 157.99M | 169.41M | 167.47M | 160.34M | 169.47M | 163.93M | 167.12M | 178.02M | 168.57M | 168.92M | 181.10M | 179.52M | 177.38M |
| Operating Income | 3.34M | 1.82M | 5.11M | - | -2.25M | -6.44M | -20.86M | - | -14.05M | -15.78M | -3.57M | - | -6.94M | 6.54M | 4.05M | - | 1.08M | 5.28M | 2.41M | - | 17.09M | -7.15M | 17.62M | - | 19.44M | 34.84M | 31.43M | 17.39M | 31.23M | 21.29M | -3.09M | 39.88M | 17.72M | 13.21M | 28.24M | -139.53M | 1.99M | 8.50M | 6.36M | 6.90M |
| Net Income | 1.26M | 8.00K | 3.09M | -2.50M | -3.85M | -7.96M | -22.16M | -3.97M | -19.87M | -19.74M | -7.60M | 4.59M | -10.68M | 2.56M | -640.00K | 8.29M | -2.77M | 2.73M | -6.09M | -4.89M | 8.16M | -7.27M | 130.12M | 14.51M | 10.37M | 19.08M | 17.66M | 6.83M | 19.88M | -693.00K | -19.54M | 25.76M | 10.86M | 8.98M | 18.89M | -143.47M | 4.81M | -4.85M | 5.43M | 2.92M |
| Diluted EPS | - | - | 0.08 | - | - | - | -0.59 | - | - | - | - | - | - | 0.06 | - | - | -0.07 | 0.06 | -0.15 | -0.12 | 0.19 | -0.17 | 2.94 | 0.32 | 0.23 | 0.42 | 0.39 | 0.15 | 0.40 | -0.02 | -0.43 | 0.51 | 0.23 | 0.19 | 0.39 | -3.11 | 0.10 | -0.11 | 0.12 | 0.07 |
| R&D Expense | 5.97M | 3.65M | 5.89M | - | 9.49M | 9.36M | 9.75M | - | 16.63M | 18.86M | 11.78M | - | 14.38M | 12.24M | 14.90M | - | 14.38M | 17.83M | 20.25M | - | 15.82M | 13.62M | 14.65M | - | 15.88M | 12.57M | 11.58M | 21.61M | 26.28M | 19.41M | 17.14M | 18.82M | 20.83M | 18.24M | 20.34M | 19.10M | 25.34M | 28.20M | 25.97M | 28.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.01M | 14.56M | 15.69M | 39.08M | 85.55M | 197.67M | 249.00M | 270.07M | 284.34M | 332.43M | 418.93M | 429.65M | 541.53M | 666.82M | 674.98M | 700.97M | 726.41M |
| Operating Income | -28.55M | -22.71M | -39.10M | -49.30M | -53.29M | -5.17M | 9.46M | -32.02M | -24.94M | 15.91M | 10.48M | 46.35M | 89.92M | 60.02M | 87.67M | -73.37M | 19.19M |
| Net Income | -31.71M | -27.15M | -43.33M | -52.28M | -63.91M | -13.72M | 1.86M | -37.95M | -42.61M | -471.00K | -11.02M | 145.52M | 41.98M | 15.91M | 41.95M | -99.56M | 7.03M |
| Diluted EPS | - | - | - | - | -1.93 | -0.39 | 0.04 | -1.02 | -1.07 | -0.01 | -0.27 | 3.33 | 0.92 | 0.34 | 0.89 | -2.15 | 0.16 |
| R&D Expense | 26.23M | 18.63M | 14.87M | 9.94M | 21.56M | 18.73M | 28.66M | 45.68M | 57.29M | 55.69M | 72.12M | 59.42M | 55.55M | 84.80M | 76.26M | 81.58M | 117.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 66.56M | 113.49M | 112.05M | 169.82M | 326.07M | 387.74M | 391.47M | 628.37M | 689.35M | 831.07M | 1.27B | 2.08B | 1.68B | 1.57B | 1.55B | 1.26B |
| Total Equity | 7.49M | -22.95M | -48.38M | 48.27M | 65.86M | 41.25M | 171.15M | 218.39M | 218.98M | 279.48M | 321.23M | 354.94M | 619.69M | 730.41M | 775.01M | 870.13M | 778.35M | 693.11M |
| Cash & Equivalents | 12.39M | 7.08M | 26.13M | 46.17M | 12.52M | 12.52M | 37.52M | 56.98M | 35.94M | 54.13M | 132.53M | 78.23M | 99.96M | 585.58M | 104.14M | 153.30M | 276.77M | 158.54M |
| Long Term Debt | - | - | 21.87M | 18.54M | 25.19M | 0 | 103.10M | 104.04M | 108.74M | - | - | - | - | - | 689.47M | 522.44M | 383.55M | 372.19M |
| Total Liabilities | - | - | 114.94M | 65.22M | 46.20M | 128.57M | 154.93M | 169.34M | 172.49M | 348.89M | 368.13M | 476.12M | 654.83M | 1.34B | 906.19M | 704.26M | 775.17M | 571.81M |
| Current Liabilities | - | - | 16.32M | 31.91M | 14.16M | 121.94M | 140.01M | 149.79M | 44.84M | 56.22M | 60.66M | 107.67M | 253.33M | 521.12M | 147.77M | 97.38M | 309.92M | 120.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - | - | 17.79M | 48.87M | 70.52M | 77.03M | 125.72M | 145.27M | 154.65M | 189.39M | 151.99M |
| Investing Cash Flow | - | - | - | - | - | - | - | - | -223.76M | 20.58M | -128.49M | -277.61M | -20.79M | -225.19M | 77.54M | -83.28M | 99.48M |
| Financing Cash Flow | - | - | - | - | - | - | - | - | 224.16M | 8.95M | 3.67M | 222.30M | 380.69M | -401.53M | -183.03M | 17.36M | -369.63M |
| Capital Expenditure | -5.51M | -6.77M | -6.17M | -18.26M | -12.17M | -22.98M | -40.30M | -24.71M | -19.27M | -14.51M | -10.16M | -37.80M | -45.87M | -30.08M | -15.16M | -10.64M | -15.33M |
| Free Cash Flow | - | - | - | - | - | - | - | - | -1.48M | 34.36M | 60.36M | 39.23M | 79.85M | 115.20M | 139.49M | 178.75M | 136.66M |
| Share Buybacks | - | 2.00K | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 25.00M | 148.33M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -190.2% | -155.9% | -249.2% | -126.1% | -62.3% | -2.6% | 3.8% | -11.9% | -8.8% | 4.8% | 2.5% | 10.8% | 16.6% | 9.0% | 13.0% | -10.5% | 2.6% |
| Net Margin % | -211.3% | -186.4% | -276.2% | -133.8% | -74.7% | -6.9% | 0.7% | -14.1% | -15.0% | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| ROE % | 138.2% | 56.1% | -89.8% | -79.4% | -154.9% | -8.0% | 0.8% | -17.3% | -15.2% | -0.1% | -3.1% | 23.5% | 5.7% | 2.1% | 4.8% | -12.8% | 1.0% |
| ROCE % | - | -45.2% | -47.9% | -50.4% | -111.3% | -2.8% | 4.0% | -9.2% | -4.4% | 2.5% | 1.4% | 4.5% | 5.8% | 3.9% | 5.9% | -5.9% | 1.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 17.12% | 6.74M | $169.73M |
| 2 | Doma Perpetual Capital Management LLC | 7.06% | 2.78M | $70.00M |
| 3 | Vanguard Portfolio Management LLC | 6.36% | 2.50M | $63.03M |
| 4 | Dimensional Fund Advisors LP | 5.24% | 2.06M | $51.93M |
| 5 | Shaw D.E. & Co., Inc. | 5.04% | 1.98M | $49.96M |
| 6 | State Street Corporation | 4.88% | 1.92M | $48.37M |
| 7 | Renaissance Technologies, LLC | 4.64% | 1.83M | $46.00M |
| 8 | Vanguard Capital Management LLC | 4.53% | 1.78M | $44.96M |
| 9 | Goldman Sachs Group Inc | 3.99% | 1.57M | $39.56M |
| 10 | Morgan Stanley | 3.54% | 1.39M | $35.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PCRX
Considering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the Details - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOTG5zeHZLdV90TzJXNTVLYS03MW9lR3czWElwVXE2VmctM2JnTTViU1RiUWFTN01ieXluc2wta1M3WmtDLVA0OWhtSmVvamFscTZmb1dSSmVHOV9sQUo3ZFdROU5UbHpsRlhXdkFzdUtlWVBmdE9Fa3ptN2ZyR2Npd2JxdkZhYk1tQnd3RX…
Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOTHZQdHBMM1M1bl9JYlFhRC1rOFFHRjNNQkoxazg5TVpsSmZ5WUl4ZmtYbHBFTy1rdjViVFowVnQ3N0FGQV9jNVVsRkxXVWZlakxrc0NYMnBlWTZObE1CWmUxTHZVejhjR2hoS05obm1MUHFpVHdOeEZ5RkxDMWZ2ekw1NjVfZlJxNXYyb3…
Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxQQXlrZHlDMU1LaWFQMEY2bUFVY21CbF9CR09USDRISGY1ajdQM241UGdIbjV4N2FmRjZyR0N6UDg3aURlSnE2ckp1bFdvN0VVSjhON2w3ekpjRzhxel81N010d3JtMlExTzJWd1NFUXpOcDVTUjlDVE9tMUJ6ZFBuT19fSXNpek5hOUtfVU…
Pacira offloads iovera° for up to $140M, keeps spasticity program - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOQnRzWGsxcndydGtHOUI5MnhUU2cxdmx0YkJQSm9NT1RwMkZPREJYbksyX1lLMV92bEdFLVdUYTNaRlA4a2hUOTlGNmY1TjNWNDZGbGRocFZneFp4Z1BEYkM1QTFsaERlb0tRTENkOTVDNXBVSVktTklKbW1xM1ZiRzBHU2poWXpHM3pLWl…
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health - ChartMill
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxOWlNZcy1QRWJKalVpekNRUk9oRFRzOW9KZ0hvZUpUQkt5T05wMGM1WFN5Z2JPR1FmRENXeU0yUGJvU0RHNDZpUHM4UDd0Q2YwNXBOeWY2X2w0TTRGLVZ3WGNnRUY3ODQ3VjZnLURhbTVTTlV0NFg5MkZjenplSzA3bDdSbkR0MXdUcFFLWk…
Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued? - Sahm
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNaGZNZFluYVBRdmVIYzdQTVd2dWhGUE40MFJxRmRzOTJrcTZqcmNVSElBR1pINThFV2NDWVhpM2J4azFBN2lkalEzVFZ5UkJjeTc2Vmh5cXQ2SGlvRTRSc0Q4TVEzY2pyb0pJaW54cHl2aVFva0Y2RmdMVG5fa3hmV1laUUUtY1llbW1vbj…
PCRX — Frequently Asked Questions
What is the current share price of Pacira BioSciences, Inc. (PCRX)?
As of 2026-07-15 16:51 PDT, Pacira BioSciences, Inc. (PCRX) trades at $25.33 on NasdaqGS. Its 52-week range is $19.16 to $27.22.
What is the market capitalisation of PCRX?
Pacira BioSciences, Inc. (PCRX) has a market capitalisation of $996.68M on NasdaqGS.
What is the P/E ratio of PCRX?
PCRX trades at a trailing price-to-earnings (P/E) ratio of 194.85. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 1.51.
What is the return on equity (ROE) of PCRX?
PCRX has a return on equity (ROE) of 0.71%. Its return on capital employed (ROCE) is 1.68%.
Is PCRX a good stock to buy?
This page provides a data-driven analysis of Pacira BioSciences, Inc. (PCRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.